aibioEWTX Edgewise Therapeutics, Inc.
Edgewise Therapeutics (EWTX) news
Top story · Jul 13, 2026 · SEC filing 8-K
Edgewise Therapeutics completes an acquisition or sale of assets
Completion of Acquisition or Disposition of Assets On July 10, 2026, Edgewise Therapeutics, Inc.
Latest Edgewise Therapeutics news
We have not published a story on Edgewise Therapeutics yet. When there is news, it will appear here.
What Edgewise Therapeutics does
Edgewise Therapeutics aims to discover medicines for serious muscle diseases. Its platform measures integrated muscle function in whole organ extracts to identify small molecule precision medicines that regulate key muscle proteins. Its most advanced candidate, sevasemten, is an orally administered, allosteric, selective fast myofiber (type II) myosin small molecule inhibitor designed to address contraction-induced muscle injury in dystrophinopathies, including Duchenne and Becker muscular dystrophy. The text says sevasemten is being studied in multiple late-stage clinical trials in Becker and Duchenne, including an ongoing pivotal cohort in patients with Becker, and that no approved therapies currently exist for Becker. The FDA granted sevasemten Fast Track designation for Duchenne in February 2024. In its cardiovascular program, EDG-7500 is an oral cardiac sarcomere modulator for hypertrophic cardiomyopathy, in a multipart Phase 2 trial in obstructive and nonobstructive HCM. The company estimates about 35,000 people in the U.S., EU-5 and Japan live with Duchenne, and 12,000 live with Becker.
| Product or program | What it is | Stage |
|---|---|---|
| sevasemten | Oral fast myosin inhibitor for Duchenne and Becker muscular dystrophy | late-stage clinical trials |
| EDG-7500 | Oral cardiac sarcomere modulator for hypertrophic cardiomyopathy | multipart Phase 2 trial |
| EDG-15400 | Cardiac sarcomere modulator for heart failure with preserved ejection fraction | Phase 1 trial |
Edgewise Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $151.4 million | $127.0 million |
| Net income (loss) | -$167.8 million | -$133.8 million |
| Cash from operations | -$143.8 million | -$109.0 million |
| Cash and equivalents | $61.1 million | $41.7 million |
Questions about Edgewise Therapeutics
What is the ticker symbol of Edgewise Therapeutics?
Edgewise Therapeutics, Inc. trades under the ticker EWTX on NASDAQ.
Where is Edgewise Therapeutics listed?
Edgewise Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Edgewise Therapeutics?
The SEC Central Index Key (CIK) for Edgewise Therapeutics, Inc. is 1710072. Its filings are on SEC EDGAR.
How many shares does Edgewise Therapeutics have outstanding?
108,604,129 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Edgewise Therapeutics listed under?
Our directory records Edgewise Therapeutics, Inc. under United States.
What does Edgewise Therapeutics do?
Our directory classifies Edgewise Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Edgewise Therapeutics?
The ISIN recorded for Edgewise Therapeutics, Inc. is US28036F1057.
Does aibio.space cover Edgewise Therapeutics?
aibio.space lists Edgewise Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Edgewise Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What does Edgewise Therapeutics develop?
Edgewise Therapeutics aims to discover medicines for serious muscle diseases. Its platform measures integrated muscle function in whole organ extracts to identify small molecule precision medicines that regulate key muscle proteins.
What is sevasemten from Edgewise Therapeutics?
sevasemten: Oral fast myosin inhibitor for Duchenne and Becker muscular dystrophy Stage: late-stage clinical trials.
What is EDG-7500 from Edgewise Therapeutics?
EDG-7500: Oral cardiac sarcomere modulator for hypertrophic cardiomyopathy Stage: multipart Phase 2 trial.
Is Edgewise Therapeutics profitable?
Edgewise Therapeutics, Inc. reported a net loss of $167.8 million for the fiscal year ended Dec 31, 2025, and used $143.8 million of cash in operations, per its annual report to the SEC.
How much does Edgewise Therapeutics spend on research and development?
$151.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Edgewise Therapeutics have?
$72.3 million in cash at Jun 30, 2026, per its 10-Q.
Investor discussion: Edgewise Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- Edgewise Therapeutics, Inc.
- CIK
- 1710072
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- EWTX (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 1715 38TH ST, BOULDER, CO, 80301
- Phone
- 720-262-7002
- Shares outstanding
- 108,604,129 as of 2026-07-31 (10-Q filed 2026-08-06)
Recent filings
Listing details
- Company
- Edgewise Therapeutics, Inc.
- Ticker
- EWTX
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US28036F1057
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction